Category: Patent & Other IP Offices
-
U.S. Supreme Court denies Google cert petition challenging USPTO’s settled expectations denials
Three other petitions for writ of certiorari, similarly questioning the agency’s validity review denials, are pending before the court.
-
UK government rejects new FRAND rate-setting track in SEP policy response
The UK government has rejected a dedicated FRAND rate-setting track in favor of exploring early judicial evaluation and non-binding IPO opinions, while leaving the existing injunction framework unchanged.
-
Dolby, MediaTek bought 40% of video codec patent families that changed hands in the U.S. over six months: USPTO records analysis
A review of recent USPTO assignment records shows Alibaba, LG, and OP Solutions selling video codec patents while Dolby, MediaTek, and licensing entities bought, in some cases, expired patents.
-
Via annual Bridge Summit to focus on AI licensing
Via Licensing Alliance’s fourth-ever annual Bridge Summit, due to take place next week, will feature AI infrastructure and data center licensing discussions throughout its conference, as well as licensor meetings dedicated to its newly launched DRAM pool.
-
EPO board of appeal rejects claim-saving approach to ambiguous amendments
The EPO Board of Appeal has rejected a claim-saving approach to ambiguous amendments in a Philip Morris e-cigarette patent dispute, holding that unresolved ambiguity can broaden a claim and create added-matter problems.
-
iPhone Duo: two long-running Apple patent families and a Liechtenstein priority filing
Apple’s iPhone Duo arrives with a long paper trail: a 2011 patent naming CEO John Ternus as inventor, a 2015 family whose foldable claims issued five months before launch, and an iPhone Duo trademark filed first in Liechtenstein in March.
-
Daiichi Sankyo loses six CNIPA administrative patent-linkage cases over mirogabalin formulation patents
Daiichi Sankyo has now lost six Chinese patent-linkage cases over generic mirogabalin after the CNIPA found two dosage strengths outside three formulation patents. The rulings show the growing importance of CNIPA’s administrative route for resolving patent disputes before generic launch.
-
EPO Enlarged Board limits mandatory description amendments in G 1/25
The EPO Enlarged Board of Appeal has ruled that amended claims do not automatically require corresponding changes to the description, while reinforcing the description’s role in claim interpretation.
-
Podcast: interview with WIPO’s Heike Wollgast on SEP mediation pledge, role of alternative dispute resolution in patent litigation
In our latest podcast episode, ip fray interviewed Heike Wollgast, who heads up the IP Disputes Section of the World Intellectual Property Organization’s Arbitration and Mediation Center.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent Court
The Munich I Regional Court has found that Accord infringed TOWA’s dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.